https://www.onclive.com/view/longer-term-data-help-shape-tki-selection-in-ros1-and-alk-nsclc2026-07-21T16:10:06.263Z2026-07-21T16:10:06.263Z https://www.onclive.com/view/study-finds-bringing-clinical-trials-closer-to-patients-expands-access-to-research2026-07-21T16:00:00Z2026-07-21T16:00:00Z https://www.onclive.com/view/eo2463-induced-cd8-t-cell-expansion-correlates-with-survival-outcomes-in-indolent-nhl2026-07-21T15:29:57.421Z2026-07-21T15:29:57.421Z https://www.onclive.com/view/alpha-dart-plus-pembrolizumab-yields-100-orr-in-elderly-recurrent-or-metastatic-hnscc2026-07-21T13:57:52.779Z2026-07-21T13:57:52.779Z https://www.onclive.com/view/adcs-and-bispecific-antibodies-across-solid-tumors-integrating-new-targets-new-data-and-new-decisions2026-07-21T13:21:15.952Z2026-07-21T13:21:15.952Z https://www.onclive.com/view/selecting-between-frontline-adcs-in-clinical-practice2026-07-21T12:05:00Z2026-07-21T12:05:00Z https://www.onclive.com/view/epcoritamab-phase-3-data-and-bispecific-antibody-differentiation-in-dlbcl2026-07-21T12:05:00Z2026-07-21T12:05:00Z https://www.onclive.com/view/how-primo-and-terzo-could-shift-community-practice2026-07-21T12:05:00Z2026-07-21T12:05:00Z https://www.onclive.com/view/lurbinectedin-sequencing-restrictions-and-real-world-treatment-patterns-in-es-sclc2026-07-21T12:05:00Z2026-07-21T12:05:00Z https://www.onclive.com/view/hr-positive-her2-negative-early-breast-cancer-emerging-endocrine-strategies-and-the-potential-role-of-giredestrant2026-07-21T12:05:00Z2026-07-21T12:05:00Z https://www.onclive.com/view/frontline-sequencing-and-impact-on-relapse-options-in-dlbcl2026-07-21T12:00:00Z2026-07-21T12:00:00Z https://www.onclive.com/view/trilaciclib-for-myeloprotection-during-induction-and-maintenance-in-es-sclc2026-07-21T12:00:00Z2026-07-21T12:00:00Z https://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-oral-serd-sequencing-and-emerging-combination-strategies2026-07-21T12:00:00Z2026-07-21T12:00:00Z https://www.onclive.com/view/future-directions-in-frontline-and-combination-therapy-for-ptcl2026-07-21T12:00:00Z2026-07-21T12:00:00Z https://www.onclive.com/view/a-closer-look-at-the-tropion-breast02-findings2026-07-21T12:00:00Z2026-07-21T12:00:00Z https://www.onclive.com/view/olverembatinib-plus-blinatumomab-yields-high-early-phase-cr-cri-rates-in-r-r-ph-cml-and-b-all2026-07-21T12:00:00Z2026-07-21T12:00:00Z https://www.onclive.com/view/emerging-agents-and-critical-gaps-in-cns-data-for-egfr-mutated-nsclc2026-07-21T12:00:00Z2026-07-21T12:00:00Z https://www.onclive.com/view/dlbcl-2026-update2026-07-20T19:30:00Z2026-07-20T19:30:00Z https://www.onclive.com/view/prame-directed-therapies-advance-melanoma-treatment-across-clinical-settings2026-07-20T16:14:05.359Z2026-07-20T16:14:05.359Z https://www.onclive.com/view/roswell-park-to-spotlight-advances-in-ai-immunotherapy-and-surgery-at-international-head-neck-cancer-meeting2026-07-20T16:00:00Z2026-07-20T16:00:00Z https://www.onclive.com/view/what-oncology-fellowship-is-really-like-jonathan-lee-md-and-chinmay-jani-md2026-07-20T15:22:11.190Z2026-07-20T15:22:11.190Z https://www.onclive.com/view/dr-falchi-on-critical-unmet-needs-and-important-next-steps-in-dlbcl2026-07-20T14:47:28.813Z2026-07-20T14:47:28.813Z https://www.onclive.com/view/tumor-board-evolving-immunotherapy-strategies-for-stage-i-iii-nsclc2026-07-20T14:47:25.246Z2026-07-20T14:47:25.246Z https://www.onclive.com/view/fda-grants-fast-track-designation-to-pelareorep-in-pretreated-scac2026-07-20T14:00:07.138Z2026-07-20T14:00:07.138Z https://www.onclive.com/view/older-age-is-independently-associated-with-inferior-survival-after-ptcy-based-unrelated-donor-hsct-in-hematologic-malignancies2026-07-20T13:00:00Z2026-07-20T13:00:00Z https://www.onclive.com/view/her2-positive-early-breast-cancer-future-directions-in-risk-adapted-treatment2026-07-20T12:10:00Z2026-07-20T12:10:00Z https://www.onclive.com/view/her2-positive-early-breast-cancer-multidisciplinary-coordination-in-adjuvant-care2026-07-20T12:05:00Z2026-07-20T12:05:00Z https://www.onclive.com/view/sonrotoclax-and-next-generation-bcl-2-inhibitors-for-treating-cll2026-07-20T12:05:00Z2026-07-20T12:05:00Z https://www.onclive.com/view/evidence-gaps-de-escalation-opportunities-and-test-selection2026-07-20T12:05:00Z2026-07-20T12:05:00Z https://www.onclive.com/view/patient-education-trial-design-post-market-surveillance-and-adoption-barriers2026-07-20T12:05:00Z2026-07-20T12:05:00Z https://www.onclive.com/view/common-themes-across-tumor-types2026-07-20T12:00:00Z2026-07-20T12:00:00Z https://www.onclive.com/view/her2-positive-early-breast-cancer-adjuvant-treatment-strategies-for-residual-disease2026-07-20T12:00:00Z2026-07-20T12:00:00Z https://www.onclive.com/view/treatment-sequencing-and-real-world-evidence-in-cll2026-07-20T12:00:00Z2026-07-20T12:00:00Z https://www.onclive.com/view/meta-10-19-elicits-high-complete-response-rate-at-ultra-low-doses-in-high-risk-r-r-dlbcl2026-07-20T12:00:00Z2026-07-20T12:00:00Z https://www.onclive.com/view/clinical-implementation-rle-supply-chain-institutional-readiness-and-access2026-07-20T12:00:00Z2026-07-20T12:00:00Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-7-122026-07-19T12:00:00Z2026-07-19T12:00:00Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-7-122026-07-18T18:49:41.746Z2026-07-18T18:49:41.746Z https://www.onclive.com/view/cd33-directed-car-t-cell-therapies-elicit-complete-remissions-in-relapsed-refractory-aml2026-07-18T11:00:00Z2026-07-18T11:00:00Z https://www.onclive.com/view/imaging-cadence-radiation-timing-and-osimertinib-dosing-frame-cns-management-decisions-in-egfr-mutated-nsclc2026-07-17T23:50:00Z2026-07-17T23:50:00Z https://www.onclive.com/view/improved-outcomes-for-high-risk-cll-remain-key-focus-for-continued-development-of-fixed-duration-regimens2026-07-17T18:57:08.195Z2026-07-17T18:57:08.195Z https://www.onclive.com/view/dr-galsky-on-the-fda-approval-of-pembrolizumab-plus-enfortumab-vedotin-in-mibc2026-07-17T18:35:01.749Z2026-07-17T18:35:01.749Z https://www.onclive.com/view/cases-and-conversations-applying-the-evidence-real-world-strategies-to-optimize-care-for-patients-with-myelofibrosis2026-07-17T17:43:36.537Z2026-07-17T17:43:36.537Z https://www.onclive.com/view/subcutaneous-pembrolizumab-faces-scrutiny-over-convenience-and-cost-for-patients-with-cancer2026-07-17T17:00:18.589Z2026-07-17T17:00:18.589Z https://www.onclive.com/view/navigating-systemic-therapy-selection-and-sequencing-in-advanced-cscc-with-neil-d-gross-md-facs2026-07-17T16:45:00Z2026-07-17T16:45:00Z https://www.onclive.com/view/china-s-nmpa-approves-iza-bren-for-pretreated-recurrent-metastatic-escc2026-07-17T16:40:00Z2026-07-17T16:40:00Z https://www.onclive.com/view/cutting-edge-drug-shows-promise-for-patients-with-nras-driven-melanoma2026-07-17T14:35:10.354Z2026-07-17T14:35:10.354Z https://www.onclive.com/view/onclive-weekly-news-quiz-7-17-2026-did-you-catch-important-milestones-in-breast-cancer-and-myeloma-myeloma-mibc-and-more2026-07-17T13:00:03.950Z2026-07-17T13:00:03.950Z https://www.onclive.com/view/addressing-unmet-need-in-second-line-nsclc-without-actionable-alterations2026-07-17T12:05:00Z2026-07-17T12:05:00Z https://www.onclive.com/view/patient-selection-sequencing-and-co-mutations-in-kras-g12c-mutant-nsclc2026-07-17T12:00:00Z2026-07-17T12:00:00Z https://www.onclive.com/view/orelabrutinib-generates-significant-survival-benefits-in-treatment-naive-cll2026-07-17T12:00:00Z2026-07-17T12:00:00Z https://www.onclive.com/view/future-directions-in-desmoid-tumor-research-and-treatment-and-clinical-practice-integration2026-07-17T12:00:00Z2026-07-17T12:00:00Z https://www.onclive.com/view/mythos-misses-prespecified-orr-end-point-with-t-dxd-in-her2-low-salivary-gland-carcinoma2026-07-16T21:24:11.445Z2026-07-16T21:24:11.445Z https://www.onclive.com/view/tumor-board-optimizing-nsclc-care-leveraging-the-latest-evidence-on-targeted-therapy-and-immuno-oncology2026-07-16T20:59:32.029Z2026-07-16T20:59:32.029Z https://www.onclive.com/view/dr-ermann-on-real-world-data-for-zanubrutinib-vs-acalabrutinib-in-older-cll2026-07-16T18:13:04.658Z2026-07-16T18:13:04.658Z https://www.onclive.com/view/experts-unpack-crucial-hematologic-oncology-data-from-asco-20262026-07-16T17:26:06.543Z2026-07-16T17:26:06.543Z https://www.onclive.com/view/dr-kenny-on-phase-2-data-with-neoadjuvant-cemiplimab-in-bcc-of-the-head-and-neck2026-07-16T16:20:00Z2026-07-16T16:20:00Z https://www.onclive.com/view/international-intel-a-glance-at-the-top-global-breast-cancer-news-from-april-june-20262026-07-16T14:44:30.406Z2026-07-16T14:44:30.406Z https://www.onclive.com/view/young-women-diagnosed-with-breast-cancer-within-3-uears-of-childbirth-may-face-more-aggressive-disease-ucla-study-finds2026-07-16T14:00:00Z2026-07-16T14:00:00Z https://www.onclive.com/view/future-directions-for-personalized-care-in-hr-positive-her2-negative-advanced-breast-cancer2026-07-16T13:00:00Z2026-07-16T13:00:00Z https://www.onclive.com/view/neoadjuvant-cemiplimab-elicits-responses-and-surgical-benefit-in-hhi-naive-bcc-of-the-head-and-neck2026-07-16T12:55:05.933Z2026-07-16T12:55:05.933Z https://www.onclive.com/view/evaluating-future-directions-for-biomarker-guided-care-in-hr-positive-her2-negative-advanced-breast-cancer2026-07-16T12:55:00Z2026-07-16T12:55:00Z https://www.onclive.com/view/addressing-testing-implementation-in-hr-positive-her2-negative-advanced-breast-cancer2026-07-16T12:50:00Z2026-07-16T12:50:00Z https://www.onclive.com/view/practical-considerations-for-molecular-monitoring-in-hr-positive-her2-negative-advanced-breast-cancer2026-07-16T12:45:00Z2026-07-16T12:45:00Z https://www.onclive.com/view/integrating-ctdna-monitoring-into-hr-positive-her2-negative-advanced-breast-cancer-care2026-07-16T12:40:00Z2026-07-16T12:40:00Z https://www.onclive.com/view/evaluating-ctdna-clearance-in-hr-positive-her2-negative-advanced-breast-cancer2026-07-16T12:35:00Z2026-07-16T12:35:00Z https://www.onclive.com/view/assessing-ctdna-dynamics-in-hr-positive-her2-negative-advanced-breast-cancer2026-07-16T12:30:00Z2026-07-16T12:30:00Z https://www.onclive.com/view/balancing-efficacy-and-quality-of-life-in-hr-positive-her2-negative-advanced-breast-cancer2026-07-16T12:25:00Z2026-07-16T12:25:00Z https://www.onclive.com/view/exploring-biomarker-guided-treatment-adaptation-in-hr-positive-her2-negative-advanced-breast-cancer2026-07-16T12:20:00Z2026-07-16T12:20:00Z https://www.onclive.com/view/evaluating-early-intervention-strategies-in-esr1-mutated-hr-positive-her2-negative-advanced-breast-cancer2026-07-16T12:15:00Z2026-07-16T12:15:00Z https://www.onclive.com/view/managing-esr1-mutated-hr-positive-her2-negative-advanced-breast-cancer-after-disease-progression2026-07-16T12:10:00Z2026-07-16T12:10:00Z https://www.onclive.com/view/optimizing-esr1-mutation-testing-strategies-in-hr-positive-her2-negative-advanced-breast-cancer2026-07-16T12:05:00Z2026-07-16T12:05:00Z https://www.onclive.com/view/selecting-between-cdk4-6-inhibitors-and-navigating-delayed-initiation2026-07-16T12:05:00Z2026-07-16T12:05:00Z https://www.onclive.com/view/lung-and-thymic-subgroup-analysis-and-safety2026-07-16T12:05:00Z2026-07-16T12:05:00Z https://www.onclive.com/view/post-combination-sequencing-and-resistance-mechanisms2026-06-18T12:05:00.000Z2026-07-16T12:05:00Z https://www.onclive.com/view/combination-tolerability-and-safety-considerations2026-06-18T12:05:00.000Z2026-07-16T12:00:00Z https://www.onclive.com/view/understanding-esr1-mediated-endocrine-resistance-in-hr-positive-her2-negative-advanced-breast-cancer2026-07-16T12:00:00Z2026-07-16T12:00:00Z https://www.onclive.com/view/case-1-individualizing-adjuvant-therapy-in-a-premenopausal-patient-with-high-risk-features2026-07-16T12:00:00Z2026-07-16T12:00:00Z https://www.onclive.com/view/safety-considerations-in-grade-3-disease2026-07-16T12:00:00Z2026-07-16T12:00:00Z https://www.onclive.com/view/personalizing-second-line-treatment-strategies-in-hr-positive-her2-negative-advanced-breast-cancer2026-07-16T11:55:00Z2026-07-16T11:55:00Z https://www.onclive.com/view/current-treatment-landscape-in-hr-positive-her2-negative-advanced-breast-cancer2026-07-16T11:50:00Z2026-07-16T11:50:00Z https://www.onclive.com/view/dr-fecci-on-immunotherapy-research-innovations-in-glioblastoma2026-07-15T20:40:32.660Z2026-07-15T20:40:32.660Z https://www.onclive.com/view/dr-stilgenbauer-on-efficacy-data-for-tacabrutideg-in-cll-from-cadance-1012026-07-15T20:23:45.026Z2026-07-15T20:23:45.026Z https://www.onclive.com/view/dr-ermann-on-data-for-real-world-treatment-burdens-in-older-patients-with-cll2026-07-15T20:15:00Z2026-07-15T20:15:00Z https://www.onclive.com/view/car-t-cell-engineering-produces-early-efficacy-signals-in-glioblastoma2026-07-15T20:13:02.098Z2026-07-15T20:13:02.098Z https://www.onclive.com/view/dr-ko-on-the-safety-profile-of-optune-pax-in-pancreatic-cancer2026-07-15T20:05:36.469Z2026-07-15T20:05:36.469Z https://www.onclive.com/view/dr-ermann-on-btk-inhibitor-selection-in-treatment-naive-cll2026-07-15T19:37:33.109Z2026-07-15T19:37:33.109Z https://www.onclive.com/view/copper-induced-cell-death-activates-immune-system-may-help-overcome-immunotherapy-resistance2026-07-15T17:00:00Z2026-07-15T17:00:00Z https://www.onclive.com/view/bpm31510-plus-chemoradiation-drives-encouraging-os-trend-in-newly-diagnosed-glioblastoma2026-07-15T16:02:25.956Z2026-07-15T16:02:25.956Z https://www.onclive.com/view/pembrolizumab-monotherapy-improves-pfs-vs-chemotherapy-in-frontline-dmmr-endometrial-cancer2026-07-15T15:30:31.713Z2026-07-15T15:30:31.713Z https://www.onclive.com/view/frontline-sac-tmt-plus-pembrolizumab-meets-pfs-end-point-in-pd-l1-negative-nonsquamous-nsclc2026-07-15T15:09:46.998Z2026-07-15T15:09:46.998Z https://www.onclive.com/view/oncology-town-hall-updates-from-chicago-oral-serds-in-hr-her2-metastatic-breast-cancer-what-the-latest-data-really-tell-us2026-07-15T14:12:05.209Z2026-07-15T14:12:05.209Z https://www.onclive.com/view/adjuvant-immunotherapy-risk-stratification-and-multidisciplinary-care-redefine-cscc-management2026-07-15T13:57:51.293Z2026-07-15T13:57:51.293Z https://www.onclive.com/view/bexobrutideg-aims-to-overcome-resistance-mutations-in-r-r-cll2026-07-15T13:01:04.365Z2026-07-15T13:01:04.365Z https://www.onclive.com/view/clinical-and-cost-impact-of-cabazitaxel-versus-lutetium-177-vipivotide-tetraxetan-lu-psma-for-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc-2026-07-15T12:54:47.314Z2026-07-15T12:54:47.314Z https://www.onclive.com/view/post-combination-sequencing-and-adc-integration2026-07-15T12:05:00Z2026-07-15T12:05:00Z https://www.onclive.com/view/second-line-treatment-decision-making2026-07-15T12:05:00Z2026-07-15T12:05:00Z https://www.onclive.com/view/from-academic-induction-to-community-dosing-building-a-workflow-that-works2026-07-15T12:05:00Z2026-07-15T12:05:00Z https://www.onclive.com/view/sequencing-considerations-and-cns-management2026-07-15T12:00:00Z2026-07-15T12:00:00Z https://www.onclive.com/view/disease-progression-workup-and-resistance-testing2026-07-15T12:00:00Z2026-07-15T12:00:00Z https://www.onclive.com/view/ezh2-inhibitor-landscape-and-final-remarks2026-07-15T12:00:00Z2026-07-15T12:00:00Z